Business
Macrophage-Directed Therapies Summit Presentation
Macrophage-Directed Therapies Summit Presentation.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n\n \n29 July 2024\n \nHemogenyx Pharmaceuticals plc \n(\"Hemogenyx Pharmaceuticals\" or the \"Company\") \nPresentation at Macrophage-Directed Therapies Summit\n \nHemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation in the 6th Macrophage-Directed Therapies Summit (\"Summit\"), which will be held on October 1-3, 2024, in Boston, MA. The Company will present its work on its proprietary Chimeric Bait Receptor (\"CBR\") platform.\n \nThe Company's CBR platform is an advanced immunotherapy designed to program or redirect innate immune cells, such as macrophages, to eliminate specific types of cancer as well as combat infections from both existing and emerging viral threats. The Company's presentation at the Summit will focus on the use of the CBR platform for the treatment of rare cancers.\n \nDr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: \"Our presentation at the Summit will provide the Company with an opportunity to further establish its unique position in the emerging field of myeloid cell therapies. It will also allow us to exchange ideas with like-minded cell therapy developers, potential collaborators, and investors.\"\n \n \nEnquiries:\n \n\n\n\n\nHemogenyx Pharmaceuticals plc\n\n\nhttps://hemogenyx.com\n\n\n\n\nDr Vladislav Sandler, Chief Executive Officer & Co-Founder\n\n\[email protected]\n\n\n\n\nPeter Redmond, Director\n\n\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSP Angel Corporate Finance LLP\n\n\nTel: +44 (0)20 3470 0470\n\n\n\n\nMatthew Johnson, Vadim Alexandre, Adam Cowl\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeterhouse Capital Limited\n\n\nTel: +44 (0)20 7469 0930\n\n\n\n\nLucy Williams, Duncan Vasey, Charles Goodfellow\n\n\n\n\n\n\n\n\n \nAbout Hemogenyx Pharmaceuticals plc\n \nHemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.\nThe Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmace...